Item 8.01 Other Events.

On April 12, 2022, Ocugen, Inc. (the "Company") issued a press release providing an update on the Company's Phase 2/3 study of COVAXIN™ (BBV152). A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits

The following exhibits are being filed herewith:





Exhibit
  No.                                      Document

  99.1     Press Release of Ocugen, Inc. dated April 12, 2022.
104      Cover Page Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses